Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
about
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypeThe history of neuromyelitis opticaChange in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIIIAquaporin 4 and neuromyelitis opticaThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesHypersensitivity Responses in the Central Nervous SystemAntibodies as Mediators of Brain PathologyUpdate on biomarkers in neuromyelitis opticaB Cells and Autoantibodies in Multiple SclerosisNeuroprotection in a novel mouse model of multiple sclerosisMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesAnti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohortHistopathology and clinical course of MOG-antibody-associated encephalomyelitisAntibody biomarkers in CNS demyelinating diseases - a long and winding roadFulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathologyChildren with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseasesThe spectrum of MOG autoantibody-associated demyelinating diseasesDistinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosisMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeOptic neuritis in neuromyelitis optica.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.Experimental models of neuromyelitis optica.Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report.An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assaysUpdate on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.Brain-reactive antibodies and disease.
P2860
Q21146662-21F7062A-59E4-4F8E-953D-27DEF74BA979Q21245248-7AB7D5A4-0106-49DB-9CCD-0A91FE131791Q21558554-CDFB069C-A2FD-4296-AE62-10F356E78C12Q22000623-5C7DF563-90E0-4C1A-80F8-0783C2B0D53AQ24613666-9D9F9D48-2335-4E98-9589-2F87708D5C9DQ26767391-E3D83DFB-5D72-453F-969D-56D0FF44BEB0Q26779177-FA8CB2EE-3288-47BE-B0A6-73B87CDADDE4Q26780374-CCA2681D-CF89-4BD7-B19E-4394884D0F4FQ26799789-ABB0632A-7A7F-4810-8561-EC9CCF0E08B7Q26801386-99C69140-F5ED-4A42-92F3-D5A2D8460708Q27302918-35A5E1CB-F945-49A8-B4AA-655416BA40A0Q28075974-9CCA7836-C64D-4360-A7AB-88F0C90FDC81Q28245749-DF5D269E-396B-4B15-8663-74C51AAEB145Q28256650-2F564DE2-2336-4575-8140-447045B2A93CQ28259551-FB4B8525-4E18-4A47-B28B-F345E07C3BA3Q28262403-EF487FB0-B715-44F6-A446-44C3119D2634Q28270042-9D6144A9-14CA-4B51-955C-1A1A22BE3ED6Q28273255-5123034D-340F-43E3-938E-1EFAFA9F1EF5Q28293355-8790C9EA-7D90-4121-9E49-835DFC61466DQ29010429-24ED798F-A2A6-4DA7-8DF1-E7F3ED54A6A2Q29036090-D73A51F0-CD80-486A-92DC-56FB93CE4424Q30371412-1BDAE33C-DD96-4E44-B120-8FE15F26A076Q30610471-CC33949D-5535-426D-AE2C-3563BCF47C2EQ30785267-AB006161-F896-4908-9F2C-22B9F4F9B960Q30832651-DE2438FC-731E-4CE6-9E9A-A8C04310FCE0Q30833332-8219D063-FA16-43FB-BD04-12A631AF3E20Q30975717-73BE697F-B1D3-44F7-937E-E1181AD0C9DEQ33591024-8A74B8BF-C0F1-47F5-82F2-D2E6BDAC224CQ33645795-2A98132A-ADDA-4C0B-8D2E-17417374E99AQ33770508-C787D2E6-48C0-4EE7-8EA8-B256C3932105Q33785380-E5DC56DD-352C-4E12-A2ED-53670F41A8A4Q34368609-7A12DB09-40F5-4A67-B5A4-0E90E78A9465Q34431835-98004B31-01D9-4681-A8F7-739C07923679Q34440538-17722C3E-4013-4DBD-8043-3ECA0C5F2D21Q34513731-25320F19-F2BD-423A-95A5-FA1E66AA97C9Q34636918-B68EC186-9118-4066-BF39-2C645DBCF0EAQ35041142-7E6F5A0C-8E88-48E9-B138-DED303676FA2Q35052199-80B70E96-E359-4BCF-9406-BDD7A0F1F790Q35208073-3991B4B5-2D0F-44F1-B3C6-E2013DDBBE38Q35458567-13AA0D0E-2573-4B00-A47F-EA8F3CC86E5C
P2860
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Complement activating antibodi ...... s optica and related disorders
@ast
Complement activating antibodi ...... s optica and related disorders
@en
type
label
Complement activating antibodi ...... s optica and related disorders
@ast
Complement activating antibodi ...... s optica and related disorders
@en
prefLabel
Complement activating antibodi ...... s optica and related disorders
@ast
Complement activating antibodi ...... s optica and related disorders
@en
P2093
P2860
P356
P1476
Complement activating antibodi ...... s optica and related disorders
@en
P2093
Andreas Lutterotti
Bettina Kuenz
Fahmy Aboul-Enein
Florian Deisenhammer
Franziska Di Pauli
Harald Hegen
Irena Dujmovic
Jelena Drulovic
Kathrin Schanda
Kevin Rostasy
P2860
P2888
P356
10.1186/1742-2094-8-184
P577
2011-12-28T00:00:00Z
P5875
P6179
1040413165